Evidence map›Paper›PMID 25886172›Full record

ArticleBMC infectious diseases2015

Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.

Chloé Wyndham-Thomas, Violette Dirix, Kinda Schepers, Charlotte Martin, Marc Hildebrand, Jean-Christophe Goffard, Fanny Domont, Myriam Libin, Marc Loyens, Camille Locht and 2 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Review on NovelFrontiers in immunology · 2018
    Pooled it
  3. Article
  4. Immunogenicity of heparin-binding hemagglutinin expressed byIranian journal of basic medical sciences · 2018
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Chloé Wyndham-ThomasLaboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium. chloe.wyndham-thomas@erasme.ulb.ac.be.
Violette DirixLaboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium. vdirix@ulb.ac.be.
Kinda SchepersImmunodeficiency unit, Hôpital Erasme, Brussels, Belgium. kindaschepers@gmail.com.
Charlotte MartinInfectious Disease, CHU Saint-Pierre, Brussels, Belgium. charlotte_martin@stpierre-bru.be.
Marc HildebrandInfectious disease unit, IRIS SUD hospitals, Brussels, Belgium. MHILDEBRAND@his-izz.be.
Jean-Christophe GoffardImmunodeficiency unit, Hôpital Erasme, Brussels, Belgium. Jean-Christophe.Goffard@erasme.ulb.ac.be.
Fanny DomontLaboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium. fan.dom@orange.fr.
Myriam LibinLaboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium. myriam.libin@ulb.ac.be.
Marc LoyensINSERM U1019, Lille, France. marc.loyens@ibl.cnrs.fr.
Camille LochtINSERM U1019, Lille, France. camille.locht@pasteur-lille.fr.
Jean-Paul Van VoorenImmunodeficiency unit, Hôpital Erasme, Brussels, Belgium. Jean.Paul.Van.Vooren@erasme.ulb.ac.be.
Françoise MascartLaboratory of Vaccinology and Mucosal Immunology, Université Libre de Bruxelles, Brussels, Belgium. fmascart@ulb.ac.be.
Erasmus Hospital · BEUniversité Libre de Bruxelles · BEInserm · FRCentre Hospitalier Universitaire de Saint-Pierre · BEHôpitaux Iris Sud · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe screening and treatment of latent tuberculosis (TB) infection reduces the risk of progression to active disease and is currently recommended for HIV-infected patients. The aim of this study is to evaluate, in a low TB incidence setting, the potential contribution of an interferon-gamma release assay in response to the mycobacterial latency antigen Heparin-Binding Haemagglutinin (HBHA-IGRA), to the detection of Mycobacterium tuberculosis infection in HIV-infected patients.

methodsTreatment-naïve HIV-infected adults were recruited from 4 Brussels-based hospitals. Subjects underwent screening for latent TB using the HBHA-IGRA in parallel to a classical method consisting of medical history, chest X-ray, tuberculin skin test (TST) and QuantiFERON-TB Gold In-Tube (QFT-GIT). Prospective clinical and biological follow-up ensued, with repeated testing with HBHA-IGRA. A group of HIV-infected patients with clinical suspicion of active TB was also recruited and tested with the HBHA-IGRA. Multiplex analysis was performed on the culture supernatants of this in-house assay to identify test read-outs alternative to interferon-gamma that could increase the sensitivity of the test.

resultsAmong 48 candidates enrolled for screening, 9 were identified with latent TB by TST and/or QFT-GIT results. Four of these 9 patients and an additional 3 screened positive with the HBHA-IGRA. This in-house assay identified all the patients that were positive for the TST and showed the best concordance with the presence of a M. tuberculosis exposure risk. During follow-up (median 14 months) no case of active TB was reported and HBHA-IGRA results remained globally constant. Fourteen HIV-infected patients with clinical suspicion of active TB were recruited. Active TB was confirmed for 6 of them among which 3 were HBHA-IGRA positive, each with very high interferon-gamma concentrations. All patients for whom active TB was finally excluded, including 2 non-tubercular mycobacterial infections, had negative HBHA-IGRA results. Multiplex analysis confirmed interferon-gamma as the best read-out.

conclusionsThe HBHA-IGRA appears complementary to the QuantiFERON-TB Gold In-Tube for the screening of latent TB in HIV-infected patients. Large-scale studies are necessary to determine whether this combination offers sufficient sensitivity to dismiss TST, as suggested by our results. Furthermore, HBHA-IGRA may help in the diagnosis work-up of clinical suspicions of active TB.

Indexed as

AdultAgedFemaleHIV-1HIV InfectionsHumansIncidenceInterferon-gammaInterferon-gamma Release TestsLatent TuberculosisLectinsMaleMiddle AgedMultiplex Polymerase Chain ReactionMycobacterium tuberculosisTuberculin Testheparin-binding hemagglutininInterferon-gammaLectins

Identifiers

PMID25886172
PMCPMC4337251
OpenAlexW1992990070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.